Protalix BioTherapeutics, Inc. (DE) (PLX) Social Stream
Protalix BioTherapeutics Inc (PLX) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Protalix BioTherapeutics Inc.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
Price Target Last Issued March 31, 2022
PLX reports an average of 756.1% for its upside potential over the past 168 days.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
PLX Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- Protalix BioTherapeutics Inc's number of analysts covering the stock is higher than nearly none of all US stocks.
- In terms of how Protalix BioTherapeutics Inc fares relative to stocks in the mid market cap category, note that its upside potential (average analyst target price relative to current price) is higher than 99.25% of that group.
- PLX has a higher average analyst price target than 5.15% of stocks in the mid market cap category.
- PLX has a lower variance in analysts' estimates than 63.18% of Pharmaceutical Products stocks.
In the Pharmaceutical Products industry, PCVX, NSTG, and MESO are the three stocks most similar to Protalix BioTherapeutics Inc regarding the price target and analyst recommendation information presented here.
Is PLX a Buy, Hold or Sell? See the POWR Ratings now!